AZD1222
AZD1222 is a biological therapy with 18 clinical trials. Currently 1 active trials ongoing. Historical success rate of 93.8%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
88.2%
15 of 17 finished
11.8%
2 ended early
1
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
EU Secondary Data Post-Authorisation Safety Study of AZD1222
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
Study of AZD1222 for the Prevention of COVID-19 in Japan
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Clinical Trials (18)
EU Secondary Data Post-Authorisation Safety Study of AZD1222
A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
Study of AZD1222 for the Prevention of COVID-19 in Japan
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19
COVID-19 Vaccines Safety Tracking (CoVaST)
AZD1222 Vaccine for the Prevention of COVID-19
All 18 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 18